Jump to content

Search the Community

Showing results for tags 'Zytiga'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 16 results

  1. Jim Marshall (not a doctor) said ... In this video Prostate Cancer Research Institute Executive Director Mark Scholz talks about a clinical trial for men who are metastatic and have rising psa on hormone therapy. The trial is testing whether adding the PARP inhibitor Lynparza (olaparib) to the super-hormone Zytiga (abiraterone) increases its effectiveness. You can find out about the clinical trial at: https://clinicaltrials.gov/ct2/show/study/NCT03732820?show_locs=Y#locn Details there include: inclusion details (things you need to get into the trial);
  2. Jim Marshall (not a doctor) said ... If you have castrate-resistant prostate cancer, common treatments that your doctor may add to your regular ADT treatment include: Docetaxel (Taxotere) Enzalutamide (Xtandi) or Abiraterone (Zytiga) Cabazitaxel (Jevtana). But what are your doctor's drug choices when the cancer is no longer under control after all three options? If you responded to docetaxel, your doctor knows you may well respond again to another dosing of docetaxel. But this increases your risk of side effects - especially peripheral neuropathy or nail di
  3. Currently the Pharmaceutical Benefits Scheme provides that Abiraterone (Brand name Zytiga) must be taken with prednisone or prednisolone. At its March 2017 meeting the PBAC approved an application that whilst Abiraterone must be taken with a corticosteroid, the corticosteroid does not necessarily have to be prednisone or prednisolone. Patients and their doctors are now able to choose the corticosteroid that they use with Abiraterone. There has been evidence that corticosteroids other than prednisone or prednisolone may have less side effects or greater benefits.
  4. Charles (Chuck) Maack

    Chuck Maack's full information about Zytiga

    Zytiga info: I compiled this information for those patients who are being prescribed Zytiga/abiraterone acetate: Zytiga/abiraterone acetate or Xtandi/enzalutamide - What is the Difference?* http://tinyurl.com/9ozr5oa Something else to be aware: Zytiga Interactions: http://tinyurl.com/ln6elg7 It came to mind wondering how many patients and/or their caregivers prescribed Zytiga/abiraterone acetate have ever taken the important time to read all the details regarding the effects that may be experienced by patients and whether or not
  5. ScienceDaily: Prostate Cancer News Taking a high-priced cancer drug with a low-fat meal can cut cost by 75% Posted: 13 Feb 2017 05:24 PM PST Taking one-fourth the standard dose of a widely used drug for prostate cancer with a low-fat breakfast can be as effective – and four times less expensive – as taking the standard dose as recommended: on an empty stomach. The finding has significant financial implications.
  6. Click here to read Malecare's report of a clinical trial which found that combining Xtandi and Zytiga and using them at the same time was NOT better then either of the drugs by themselves.
  7. Paul Edwards

    Duration of Zytiga Response

    From Joel Novak at Malecare: "In a small (n=161 men) retrospectively study, the researchers examined patient characteristics, types and duration of prostate cancer therapies to see what parameters might effect the duration of Zytiga response. The researchers found that the lower the PSA at the time Zytiga was started, the longer primary ADT duration, no prior exposure to ketoconazole, no prior chemotherapy and longer chemotherapy duration were associated with a longer response to Zytiga.
  8. Joel Nowak of Malecare reports on an abstract presented at the 2016 American Society of Clinical Oncology (ASCO) Scientific Meeting about how abiraterone (brand name Zytiga) and enzalutamide (brand name Xtandi) may cause cognitive impairment and mood changes. Interestingly the research showed that these side effects were more prevalent with enzalutamide than with abiraterone. Click on this link to read the Malecare report..
  9. Jim was away in Sydney with a swag of other members representing our group at a meeting with Janssen, the suppliers of the drug Zytiga. As a result of this, Jim asked me to chair our phone in conference in his absence. We had no guest speaker at our gathering which made life a little easier for me as our talks would be based on a round table discussion among members. I had the feeling it might be a bit dull without a guest and members be reluctant to come forward and speak on issues. With this in mind I prepared some topics prior to the meeting just in case. I needn't have worried as right fro
  10. You will have noticed that the other members of our Executive Committee (Alan Barlee, Nev Black, Paul Hobson, Tony Maxwell) make an enormous contribution to our monthly phone-in meetings, to information and discussion posted on our website (JimJimJimJim.com), and to general support of our members by phone, email, and at Face-to-a-name members' meetings. What you may not be aware of is that your Executive Committee also spends much time and effort in advocacy duties on behalf of the group. Below are some advocacy events held during the past year. Please be aware that wh
  11. Respected prostate cancer advocate, Joel Novak from Malecare, believes that Xtandi is superior to Zytiga. Click on this link to read his reasons why he thinks this. Do you agree?
  12. I think it's important to pass on this information, particularly for those men whose ADT resulted in the prescribing of Zytiga/abiraterone acetate. I am working with a patient on ADT medications including Zytiga, also experiencing cardio issues, and recently edema. With ADT known to play a role in hypertension, cardio issues, diabetes, edema (swelling caused by excess fluid) , and other issues, among which this patient is experiencing, he was recently prescribed the medication Spironolactone by a cardiologist to help with his edema. Spironolactone turned out to have a very bad
  13. At its November meeting the Pharmaceutical Benefits Advisory Committee was considering whether Enzalutamide ( Brand name Xtandi) should be made available on the Pharmaceutical Benefits Scheme (refer to this previous post on the subject) One of the members in last week's teleconference asked when would we know the outcome of that meeting? Today the Pharmaceutical Benefits Advisory Committee published the outcomes from its July meeting. At this rate we won't know the outcomes of their November meeting until April next year. [Edit 18 December 2015 PBAC published its recommendation
  14. Paul Edwards

    Taking Abiraterone (Zytiga) with Food

    For a while now there have been questions about whether taking abiraterone with food as opposed to without food could be clinically beneficial for patients. Some studies suggest that: It might be possible to reduce the side effects of abiraterone and prednisone by taking a lower dose of these drugs with food; and It might be possible to increase the benefit of a standard dose of abiraterone by taking the drug with food but there might be a risk of increased side effects in doing this. Taking abiraterone with food is contrary to the manufacturer’s instructions. You should not do this w
  15. AR-V7 is an androgen receptor variant which, if found in the blood stream, disables the effectiveness of either Xtandi/enzalutamide or Zytiga/abiraterone acetate. I have prepared a summary of recent research about AR-V7 which is available at http://tinyurl.com/qbgpezo [Ed - Chuck's paper mentions blood tests for Circulating Tumour Cells (CTC) and AR-V7. These tests are not routinely available in Australia.]
  16. Patients taking Zytiga need to be aware that Zytiga may have adverse interactions with many common drugs. This is because many doctors are unaware of these drug interactions. So long as you are aware of this issue, it can be easily managed. It does not mean that you should stop using Zytiga. This is one of the key messages in the most recent video (28 August 2014) by Dr Charles Myers Jnr (nickname Snuffy Myers) in which he talks about Zytiga. See this Dr Myers Video at: http://askdrmyers.wordpress.com/2014/08/28/zytiga-pca-remissions/ OR http://tinyurl.com/mggrz7x
×
×
  • Create New...